Glioblastoma: new treatment strategies

Glioblastoma is the most common and most aggressive type of brain tumor. Despite advances in cancer treatment, the prognosis for patients with glioblastoma remains very poor: only 10% survive five years after diagnosis. It is therefore essential to intensify specific research efforts and propose new therapeutic approaches.

OUR CHALLENGE

Finding effective therapeutic strategies

Paris Brain Institute is striving to meet this challenge by working with leading universities and research centers around the world to fill the knowledge gap about the cells that make glioblastomas so resistant to treatment.

An international scientific partnership

Mehdi Touat from Paris Brain Institute and Keith Ligon from Harvard Medical School (United States) are joining forces to accelerate the discovery of new treatments for patients with glioblastoma. The ambition is to develop new treatment strategies using the latest research approaches in cancer and biology.

Expanding the team to advance research

Funding for the project will enable Paris Brain Institute to recruit three new experts to research new methods for mapping the heterogeneity of tumor cells and the microenvironment in order to study resistance to treatment. They will focus on genetic screening and growth monitoring and will analyze the complex interaction between the tumor and the immune microenvironment, using advanced spatial transcriptomics.

At Harvard, a new researcher will develop immunofluorescence tests to study how tumor cells rapidly adapt to exogenous environmental stress.